User tried various hair loss treatments with limited success. RU58841 was effective but caused side effects, now trying Eucapil and continuing Finasteride.
GHK-RU58841 is used for hair loss, with positive results when combined with finasteride, stemoxydine, redensyl, and alfatradiol. Users report effectiveness after adding finasteride.
A user needs to stop finasteride for 7 days to donate blood due to haemochromatosis. They are concerned if this break will affect their hair loss progress after 6 weeks of use.
RU58841 is discussed as an effective hair loss treatment, with some users experiencing regrowth and reduced shedding, but concerns about safety and sourcing are raised. Users advise against purchasing from Amazon, recommending reputable sources and cautioning about potential side effects like cardiovascular issues.
Procyanidin B2, a compound derived from Annurca apples, as a potential treatment for pattern hair loss. Several clinical studies were mentioned, which found that procyanidin B2 could increase hair growth, density, and keratin content. Other treatments such as Minoxidil, Finasteride, and RU58841 were not discussed.
The post discusses the potential of GT20029 in treating hair loss, questioning if it will replace finasteride or be used alongside existing treatments. A reply indicates that its role is still uncertain.
The conversation provides a detailed list of blood tests recommended before starting finasteride to establish a baseline for monitoring potential side effects. A shorter list is also provided for those with limited funds, and the user shares personal experience of using finasteride without issues for about nine years.
The user shared their 4.5-month progress using oral finasteride, topical minoxidil, and oral dutasteride, along with biotin, vitamin D, saw palmetto, and multivitamins. They use a combination of finasteride and dutasteride weekly, with micro-stamping, to address hair loss.
Pelage Pharmaceuticals received $120 million in Series B funding for hair loss treatment development. The conversation expresses excitement and anticipation for the release and effectiveness of the treatment.
New hair loss treatments like VDPHL01, PP405, Gt20029, and Breezula are anticipated, with VDPHL01 possibly releasing in 2027/28. Current treatments include finasteride, dutasteride, and minoxidil, but new options are eagerly awaited.
The user experienced high liver enzyme levels, possibly due to topical finasteride or supplements, and decided to stop using finasteride while continuing minoxidil. After stopping finasteride and supplements, liver levels returned to normal, suggesting finasteride or supplements might have been the cause.
The user's 42 month experience using finasteride for hair loss, their opinion on minoxidil use and the potential of pyrilutamide and another Chinese drug as treatments.
The conversation discusses hair loss treatments, specifically mentioning Minoxidil, finasteride, and RU58841. It also references Epibiotech's hair multiplication and cell therapy as potential solutions.
User experiences slow hair regrowth despite using finasteride, topical minoxidil, and supplements like biotin, zinc, and collagen. They seek advice on addressing overall slow hair regrowth.
BackToTheFutehair's 3.5 month progress update on their hair loss treatment regimen of finasteride, minoxidil, and microneedling which has led to a significant improvement in thickness and life to the hair. Others have provided encouragement and advice for future treatments.
The conversation discusses the absorption and effectiveness of PG-free versus PG versions of RU58841, with some users believing PG improves efficacy while others see no difference. Concerns about RU58841's potential side effects on the endocrine system are also mentioned, with one user considering switching to pyrilutamide.
The user stopped using finasteride due to side effects and switched to RU58841, which seems to be working for hair regrowth. They are considering RU58841 and minoxidil as long-term treatments, while others discuss the safety and effectiveness of these options.
A 27-year-old male with diffuse hair loss, including the donor area, did not respond to finasteride, dutasteride, or minoxidil. He suspects his hair loss may be linked to a mild connective tissue disorder, possibly affecting the structural support of hair follicles, rather than being purely hormonal.
After 4 months of using topical finasteride and minoxidil, blood tests showed increased E2, Test, and Prolactine levels. The user is concerned about potential side effects like gyno and is seeking advice on managing these values.
A man stopped taking finasteride, a hair loss treatment, to improve his fertility. His sperm count and motility increased after stopping the medication, but sperm shape did not change.
The conversation is about a person using dutasteride and minoxidil for hair loss, considering adding RU58841 and PP405 for more density. They are seeking advice on using these treatments and exploring other options like GT20029.
Pelage executives' hairlines were discussed, with speculation about them using PP405 for hair regrowth. Concerns were raised about using untested drugs, with some suggesting executives might not risk using them without safety data.
A 30-year-old man is considering quitting Finasteride due to sexual side effects, including reduced libido and difficulty reaching orgasm, despite its effectiveness in treating hair loss. He is exploring other factors like relationship issues and potential low testosterone, and is considering getting blood work done.
CB-03-01 is considered a failed treatment for hair loss, with future hopes pinned on PP-405 and GT-20029, expected by 2030. Alternatives like hair transplants and SMP are discussed, while some users express frustration over the slow progress of treatments like Breezula.
A potential treatment for hair loss that involves injecting fat into the scalp; the role of testosterone and estrogen in thinning fat tissue under the skin; research on using lard to treat androgenic alopecia, as well as PRP + ACELL/amniotic stem cell treatments; and ongoing clinical trials by doctors involved in the study.
HMI-115 is a new drug developed by Bioinvent and licensed by Bayer, with mixed opinions on its potential effectiveness. Some users are skeptical and prefer proven treatments like Minoxidil, finasteride, and RU58841.
The conversation discusses hair loss treatments, specifically Minoxidil, finasteride, and RU58841. Concerns are raised about the lack of studies on RU58841 and its potential effects.
The conversation is about the best way to take finasteride for hair loss, questioning whether it should be taken with food or on an empty stomach for optimal results. People are sharing their experiences with taking finasteride alongside meals.
Stopping finasteride may reduce water retention or alter fat distribution, leading to a leaner face. Hormonal changes, like reduced DHT or increased estrogen, could cause these effects.